Nel Gets $20 Million from Nikola, Fortescue Deals
By Dominic Chopping
Nel will receive around $20 million after a previous deal with Nikola was reworked and at the same time the Norwegian hydrogen company signed a supply deal with Fortescue.
Nel previously entered a supply agreement with electric-vehicle maker Nikola, but the companies have agreed to cancel that deal and instead sign a new agreement for different equipment, with Nel receiving around $9 million.
In addition, Nel will receive around $11 million from Fortescue. The Australian mining group has acquired Nikola's Phoenix Hydrogen Hub and the deal includes the installation of electrolyser equipment previously delivered by Nel to Nikola.
The payment will cover updated guarantees and warranties for the equipment and changes in the scope of delivery.
Nel shares trade 7.3% higher at NOK5.64.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
February 02, 2024 09:29 ET (14:29 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track